🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Coming in to #ASCO24, it was obvious that ADCs were a #hottopic, but they are truly inescapable: in every direction, in seemingly every tumor type, they are being investigated and taking center stage (literally). ADCs have progressed to Generation Next: let's see what it brings.

Treatment has to be TOLERABLE before it can be EFFECTIVE (even allowing for the understandable difficulty healing in time for adjuvant FLOT, I don't understand the ~1/3rd of patients who couldn't complete pre-op in CROSS, especially when it was <10% over a decade ago!) #ASCO24

Always one of the best parts of #ASCO !

Caught up with so many of my Canadian 🇨🇦 besties at #ASCO24 ⁦Sharlene Gill, MD, MPH, MBA, FASCO⁩ ⁦Jonathan Loree⁩ !

Appreciate the KEY TAKEAWAYS at #ASCO24 , Kimmie Ng, MD, MPH ASCO !

EA#2174 NCI CTEP Clinical Research: A phase II/III study of perioperative nivo/ipi in locally adv esophageal and GEJ adenoCA. Though NS benefit for pCR (21% vs. 24.8%). 👏Dr. Jennifer Eads Penn Medicine - Abramson Cancer Center for discussing the IMP of #cancerresearch in #rarecancers. ECOG-ACRIN Cancer Research Group #ASCO24 @asco

#ASCO24: GIANT study results show no difference in OS and high Gr3/4 toxicity in both dose-reduced chemo arms. Study demonstrates the role of chemotherapy in this patient population. ⁦Efrat Dotan MD⁩ ⁦OncoAlert⁩

#ASCO24: NRG 0848 final results show no benefit of added post-op CRT to historic chemo in R1 PDAC but possible benefit in pN0. Future trials of post-op CRT with modern adjuvant chemo are planned. ⁦Dr. Nina Niu Sanford⁩ ⁦NRG Oncology⁩ ⁦

#ASCO24: Mature CHECKMATE 90W IPI3/NIVO1 in unresectable #HCC vs TKI had significantly improved OS and RR of 36%. Another 1st line option. 29% use of high dose steroids for immune AEs. ⁦OncoAlert⁩ ⁦Dr. Cathy Eng ⁩ Laura Goff⁩⁩ ⁦Syed A. Ahmad⁩

Updated DYNAMIC results support the routine use of #ctDNA to guide adjuvant chemo decisions in stage II #coloncancer ; including pT4. Jonathan Loree Pashtoon Kasi MD, MS Mark Whiteford Manju George MVSc PhD Rectal Cancer Survivor Fight Colorectal Cancer

NICHE-2 published in NEJM —what an elegant work from super star Myriam Chalabi and senior John Haanen ! Study presented #ESMO22 and started the hashtag #ChalabiPlot => near 100% pathologic response in dMMR colon cancer! OncoAlert

Accrual has begun for NEO-RT trial! Appreciate the support of Jason Zell Joe Carmichael MD UC Irvine Surgery UCI Health , among the first to enroll patients! Keep it up!

First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated #coloncancer, OS HR=0.4. Patients are asking: do we recommend COX-2 for the 20% with mut PIK3CA❓ Need to do NGS for all stage III CRC. Journal of Clinical Oncology

🌍🔬 The 2024 ENETS guidance paper for managing well-differentiated small intestine neuroendocrine tumours (#Si-NET) is out! It emphasises the importance of adequate biochemical assessment, staging, and multidisciplinary treatment decisions. #MedEd ow.ly/USu150Syga9

As presented at #ASCO23 - I offer PRODIGE 23 strategy with induction FOLFIRINOX to all patients with high-risk #rectalcancer. Or JANUS trial, whenever possible. Josh Smith, MD, PhD, FACS Mark Whiteford Thomas George MD, FACP, FASCO William A Hall, MD Arvind Dasari, MD, MS

⁦SWOG Cancer Research Network⁩ AIMS #rectalcancer trial results: The diet modification intervention significantly reduced LARS - mean scores ⬇️ from Major to Minor. This could help patients with LARS. ⁦⁦Jason Zell⁩ ⁦⁦⁦COLONTOWN⁩ ⁦Fight Colorectal Cancer⁩ search.app/iXob3FRYasPZMK…

We have data now to personalize #rectalcancer treatment. Based on tumor factors and patient preferences. Gone are the days where most patients are treated the same way. These ⁦ASCO⁩ guidelines should help! ascopubs.org/doi/10.1200/JC…

Summertime is fire time in the Columbia River Gorge. Stay fire 🔥 safe! Not quite like the romantic commuter pics posted by ⁦Thor Halfdanarson⁩, but still beautiful here!

Very cool cross-trial comparison of 1st line PD1 + CTLA-4 versus PD1 + LAG-3 strategy (in advanced melanoma). Similar efficacy but slightly better safety with LAG-3 combo. Journal of Clinical Oncology Improves our understanding of the 3rd CPI. OncoAlert ascopubs.org/doi/full/10.12…

Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum ⁦AnnalsSurgOncology⁩ link.springer.com/article/10.124…